Novo Nordisk shares pop 10% on early-stage weight loss drug trial results

Shares of Novo Nordisk surged 10% following positive early-stage results for its once weekly amycretin obesity drug, which led to a 22% weight reduction in obese and overweight patients compared to a 2.0% weight gain in the placebo group. The trial showed promising results for amycretin, a treatment that targets the same gut and pancreas hormones as Novo Nordisk’s flagship obesity drug Wegovy and diabetes treatment Ozempic. Novo Nordisk is also developing an amycretin obesity pill, with early-stage trials demonstrating a 13.1% weight loss after 12 weeks and mild-to-moderate side effects.

Full Article